CAT
Caterpillar Inc.
CAT has the edge over CYRX overall, supported by stronger modeled upside and stronger fundamentals.
CYRX
Cryoport, Inc.
CYRX offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
CAT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
CAT's revenue, profitability, cash flow and balance sheet are all currently healthy.
CYRX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Under pressure | |
| Weak |
CYRX's revenue is currently healthy, but its profitability, cash flow and balance sheet are under pressure.
CAT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $380 | -37% |
| Fair | 18x | $461 | -24% |
| Forward | 20x | $605 | — |
| Current | 24x | $605 | — |
| Expensive | 33x | $840 | +39% |
Historical ranges are pointers, not guarantees.
CAT's PE is in its expensive range at 24x. If earnings grow as analysts expect, today's price would be 20x next year's earnings, in its fair range.
CYRX PE Valuation
CYRX has no meaningful PE right now: it lost money over the past year.
CAT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Moderate | |
| Low |
Analysts expect earnings and revenue growth for CAT, with profitability improving. However, they disagree widely on these estimates.
CYRX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect CYRX's losses to shrink, with revenue growing.
CAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $30.32 | +19% |
| Q3 2026 | $25.48 | +31% |
| Q2 2026 | $23.23 | +18% |
| Q1 2026 | $20.08 | -2% |
| Q4 2025 | $18.81 | -15% |
| Q3 2025 | $19.46 | -9.7% |
| Q2 2025 | $19.64 | -10% |
| Q1 2025 | $20.50 | -7.4% |
| Q4 2024 | $22.05 | +9.6% |
CAT has the edge over CYRX on earnings quality, reporting a profit while its opponent remains loss making.
CYRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.89 | -176% |
| Q2 2026 | -$0.82 | -162% |
| Q1 2026 | $1.43 | +$3.77 |
| Q4 2025 | $1.40 | +$3.89 |
| Q3 2025 | $1.17 | +$4.56 |
| Q2 2025 | $1.33 | +$5.01 |
| Q1 2025 | -$2.34 | +$0.14 |
| Q4 2024 | -$2.49 | -$0.28 |
CYRX has swung to a loss: it lost $0.89 per share over the past year, after a profit the year before.
CAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.7B | +17% |
| Q2 2026 | $20.5B | +24% |
| Q1 2026 | $17.4B | +22% |
| Q4 2025 | $19.1B | +18% |
| Q3 2025 | $17.6B | +9.5% |
| Q2 2025 | $16.6B | -0.7% |
| Q1 2025 | $14.2B | -9.8% |
| Q4 2024 | $16.2B | -5% |
CAT has the edge over CYRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +3.1 points |
| Q2 2026 | 21% | +3.6 points |
| Q1 2026 | 18% | -0.4 points |
| Q4 2025 | 14% | -4.1 points |
| Q3 2025 | 17% | -2.2 points |
| Q2 2025 | 17% | -3.6 points |
| Q1 2025 | 18% | -4.2 points |
| Q4 2024 | 18% | -0.3 points |
CAT has the edge over CYRX on profitability, with a higher operating margin.
CYRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2M | +14% |
| Q2 2026 | $49M | +7.7% |
| Q1 2026 | $47.8M | +16% |
| Q4 2025 | $45.5M | -24% |
| Q3 2025 | $44.2M | -22% |
| Q2 2025 | $45.5M | -21% |
| Q1 2025 | $41M | -25% |
| Q4 2024 | $59.5M | +4% |
CYRX's revenue is recovering but still below its 2022 peak: $50M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -18% | +4.9 points |
| Q2 2026 | -21% | +0.7 points |
| Q1 2026 | -20% | +3 points |
| Q4 2025 | -22% | +1.3 points |
| Q3 2025 | -22% | +6.5 points |
| Q2 2025 | -21% | +116 points |
| Q1 2025 | -23% | +16 points |
| Q4 2024 | -23% | +99 points |
CYRX's operating margin was −18% last quarter, up 4.9 points from the same quarter a year ago.
CAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.7B | +19% |
| Q2 2026 | $3.8B | +47% |
| Q1 2026 | $1.1B | +97% |
| Q4 2025 | $2.7B | +0.1% |
| Q3 2025 | $3.1B | -1.5% |
| Q2 2025 | $2.6B | -4.2% |
| Q1 2025 | $579M | -63% |
| Q4 2024 | $2.7B | -22% |
CAT has the edge over CYRX on cash generation, producing positive trailing cash flow while its opponent burns cash.
CYRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$40K | +$1.2M |
| Q2 2026 | -$8M | +$3.7M |
| Q1 2026 | -$6.2M | +$1.3M |
| Q4 2025 | -$4.5M | +$6.2M |
| Q3 2025 | -$1.3M | +$2.5M |
| Q2 2025 | -$11.7M | +$119K |
| Q1 2025 | -$7.5M | -$239K |
| Q4 2024 | -$10.7M | -$1.6M |
CYRX has burned cash in almost every quarter: −$19M over the past year, against −$31M the year before.
CAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -1.6M shares |
| 1 year | -2.1% | -9.9M shares |
| 3 years | -10% | -51.7M shares |
| 5 years | -16% | -86.7M shares |
| Available history | -19% | -107M shares |
CAT has the edge over CYRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.2B |
| Q2 2026 | $1.5B |
| Q1 2026 | $5B |
| Q4 2025 | $340M |
| Q3 2025 | $362M |
| Q2 2025 | $828M |
| Q1 2025 | $3.7B |
| Q4 2024 | $640M |
CAT spent $8.1B buying back its own shares over the past year, up 47% from the year before.
CYRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +211K shares |
| 1 year | +1.1% | +529K shares |
| 3 years | +3.6% | +1.7M shares |
| 5 years | +9.8% | +4.5M shares |
| Available history | +52% | +17.3M shares |
CYRX has 51M diluted shares, up 1.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $2M |
| Q3 2025 | $3.7M |
| Q4 2022 | $4.6M |
| Q3 2022 | — |
| Q2 2022 | $25M |
| Q1 2022 | $8.3M |
CAT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | 2.0x | Healthy |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | 1.6x | Healthy |
CAT has more cash than debt.
CYRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2021 | 110.0x | High |
| Q3 2021 | 24.2x | High |
CYRX's net debt is more than 20 years of its operating earnings (EBITDA).
CAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.7 | Neutral |
| Stochastic | 6.7 | Oversold |
CAT's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
CYRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.7 | Overbought |
| Stochastic | 78.1 | Neutral |
CYRX's weekly RSI is 72 (overbought) and its Stochastic is 78 (neutral).
CAT PE vs Industrials Sector
| Metric | CAT | Sector median | Relative |
|---|---|---|---|
| PE | 24x | 24x | 1.3% below |
| PE % | 69 | 58 | 11 pts above |
CAT is trading at 24x earnings, in line with the Industrials sector's median of 24x.
CYRX PE vs Industrials Sector
| Metric | CYRX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 24x | — |
CYRX has no meaningful PE right now: it lost money over the past year.
CAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $709.0 | 15% below |
| 20 week MA | $797.0 | 24% below |
| 50 week MA | $771.3 | 22% below |
| 100 week MA | $586.7 | 3.2% above |
| 200 week MA | $443.1 | 37% above |
CAT has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 37% above its 200-week average.
CYRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.9 | 12% above |
| 20 week MA | $16.7 | 20% above |
| 50 week MA | $13.1 | 53% above |
| 100 week MA | $10.4 | 94% above |
| 200 week MA | $12.4 | 63% above |
CYRX has the edge over CAT on trend strength, trading above more of its moving averages.
CAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $148.3 | $179.6 | +21% |
| 2021 | $179.6 | $206.2 | +15% |
| 2022 | $206.2 | $239.9 | +16% |
| 2023 | $239.9 | $295.7 | +23% |
| 2024 | $295.7 | $364.9 | +23% |
| 2025 | $364.9 | $583.0 | +60% |
| 2026 YTD | $583.0 | $605.3 | +3.8% |
CAT has finished every year since 2020 higher, and it's up 3.8% so far in 2026.
CYRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.2 | $45.8 | +182% |
| 2021 | $45.8 | $59.5 | +30% |
| 2022 | $59.5 | $16.4 | -72% |
| 2023 | $16.4 | $15.5 | -5.5% |
| 2024 | $15.5 | $7.80 | -50% |
| 2025 | $7.80 | $9.66 | +24% |
| 2026 YTD | $9.66 | $20.1 | +108% |
CYRX has the edge over CAT on returns for 2026, with the stronger performance.